To embed, copy and paste the code into your website or blog:
The Chief Judge of the U.S. Court of Appeals for the Federal Circuit Sharon Prost, has quipped that, with her experience in both the legislative and judicial branches of government, she is a “walking separation of powers.”
1 Prior to her appointment to the Federal Circuit in 2001, where she has presided as chief since 2014, she served as a lawyer for the Senate, including as Senator Orrin Hatch (R-Utah)’s chief counsel on the Senate Judiciary Committee. With this resume, Judge Prost has amassed decades of exposure to and expertise with IP issues affecting the pharmaceutical industry.
Thursday, March 4, 2021
The Illinois Biometric Information Privacy Act (“BIPA”) continues to attract litigation, and the battle continues as to what allegations of a BIPA violation may proceed in the federal courts. As you will recall, BIPA was enacted in 2008 to protect the privacy of personal biometric data. Section 15(a) of BIPA requires a company to publicly post a general notice about the company’s biometric data retention periods. 740 Ill. Comp. Stat. 14/15(a). Section 15(b) of BIPA requires a company to provide specific notice and obtain consent from the particular person whose biometric information is collected.
Id. at 14/15(b). BIPA also bans the sale or trade of personal biometric information for profit.
To embed, copy and paste the code into your website or blog:
On February 23, 2021, a Federal Circuit panel of Chief Judge Prost, Judge Newman, and Judge Moore reheard oral argument in
GlaxoSmithKline LLC v. Teva Pharms. USA, Inc. As discussed in our previous post, on February 9, 2021, the panel issued an order granting Teva’s petition for rehearing, vacating the prior October 2, 2020 judgment and withdrawing the October 2, 2020 opinion. The panel limited the oral argument to the issue of whether there is substantial evidence to support the jury’s verdict of induced infringement during Teva’s “skinny label” period from January 8, 2008 through April 30, 2011.
Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs
Geneos expands its lead program for treating patients with advanced hepatocellular carcinoma
Geneos adds to its leadership team
News provided by
Share this article
Share this article
PLYMOUTH MEETING, Pa., March 3, 2021 /PRNewswire/ Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million in financing. The financing was led by Korea Investment Partners (KIP) – Global Bio Fund with strong participation from all existing Series A investors including, notably, Santé Ventures and Inovio Pharmaceuticals, Inc. (NASDAQ: INO). The new investment follows the previously announced initial financing of $10.5 million in February 2019. In conjunction with the financing, Mr. Sangwoo Lee, Managing Director Korea In